Incyte Corporation (INCY)

NASDAQ: INCY · IEX Real-Time Price · USD
83.13
+2.45 (3.04%)
At close: Dec 2, 2022 4:00 PM
83.00
-0.13 (-0.16%)
After-hours: Dec 2, 2022 5:14 PM EST
3.04%
Market Cap 17.95B
Revenue (ttm) 3.33B
Net Income (ttm) 876.05M
Shares Out 222.42M
EPS (ttm) 3.92
PE Ratio 21.21
Forward PE 17.30
Dividend n/a
Ex-Dividend Date n/a
Volume 1,651,710
Open 80.28
Previous Close 80.68
Day's Range 80.01 - 83.35
52-Week Range 64.32 - 84.86
Beta 0.69
Analysts Buy
Price Target 88.74 (+6.7%)
Earnings Date Nov 1, 2022

About INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinica... [Read more]

Industry Biotechnology
IPO Date Nov 4, 1993
CEO Herve Hoppenot
Employees 2,094
Stock Exchange NASDAQ
Ticker Symbol INCY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 26 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is 88.74, which is an increase of 6.75% from the latest price.

Price Target
$88.74
(6.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia

WILMINGTON, Del. & HONG KONG--( BUSINESS WIRE )--Incyte (NASDAQ:INCY) and CMS Aesthetics, a dermatology medical aesthetic company and subsidiary of CMS (HKEX: 00867), today announced that the companies ...

2 days ago - Business Wire

Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

3 days ago - Zacks Investment Research

7 Undervalued Biotech Stocks to Buy Before They Boom

You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.

5 days ago - InvestorPlace

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.

1 week ago - Zacks Investment Research

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--( BUSINESS WIRE )--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November and December:

2 weeks ago - Business Wire

7 Cash-Rich Stocks to Buy for Peace of Mind

Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes thei...

1 month ago - InvestorPlace

2 Biotech Stocks That Could Make You Richer

Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.

Other symbols: VRTX
1 month ago - The Motley Fool

Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates

Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.

1 month ago - Zacks Investment Research

Incyte (INCY) Q3 Earnings and Revenues Miss Estimates

Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

4 Top-Rated Stocks to Buy Now for Solid Earnings Growth

Invest in stocks like e.l.f. Beauty (ELF), Monarch Casino & Resort (MCRI), Incyte (INCY) and Hubbell (HUBB) at the moment for superb earnings growth.

Other symbols: ELFHUBBMCRI
1 month ago - Zacks Investment Research

Earnings Preview: Incyte (INCY) Q3 Earnings Expected to Decline

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

A Bear Market Rally or Markets Forming a Solid Base: 5 Picks

We have narrowed our search to five large-cap U.S. companies with strong potential for the rest of 2022. These are: IBKR, INCY, WMB, HUBB and LW.

Other symbols: HUBBIBKRLWWMB
1 month ago - Zacks Investment Research

Is Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes"

Incyte (INCY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

1 month ago - Zacks Investment Research

INCY vs. GMAB: Which Stock Is the Better Value Option?

INCY vs. GMAB: Which Stock Is the Better Value Option?

Other symbols: GMAB
1 month ago - Zacks Investment Research

Incyte to Report Third Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 1, 202...

1 month ago - Business Wire

2 Cathie Wood Stocks That Are Beating the Market This Year

One is doing much better than the other year to date, but they both have solid prospects ahead.

Other symbols: VRTX
1 month ago - The Motley Fool

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United...

1 month ago - GlobeNewsWire

Incyte Names New Member to Its Board of Directors

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Names New Member to Its Board of Directors

2 months ago - Business Wire

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Mon...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

2 months ago - Business Wire

Incyte (INCY) Down 2.9% Since Last Earnings Report: Can It Rebound?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research